Context Therapeutics Inc

NASDAQ:CNTXUnited States

Context Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of patients living with solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors. Its preclinical program, CTIM-76, is an anti-Claudin 6 x anti-CD3 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, lung, and testicular, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is a Claudin 6 and CD3 bispecific antibody capable of binding to tumor cells expressing Claudin 6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement. Claudin 6 is expressed on multiple solid tumors such as ovarian, lung and testicular.

Contact Information

Headquarters

2001 Market Street, Suite 3915 Unit #15PHILADELPHIA, PA, United States 19103

Phone

267-225-7416

Fax

302-655-5049

Executives

Independent Chairman of the Board

Richard Berman

President, Chief Executive Officer, Director

Martin Lehr

Chief Financial Officer, Treasurer

Jennifer Minai-Azary

Senior Vice President - Operations

Christopher Beck

Vice President - Clinical Operations

Priya Marreddy